利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.033 秒)

    Hydroisoindoline tachykinin receptor antagonists
    1.
    发明申请
    Hydroisoindoline tachykinin receptor antagonists 有权
    羟基异吲哚啉速激肽受体拮抗剂

    公开(公告)号：US20050165083A1

    公开(公告)日：2005-07-28

    申请号：US11043213

    申请日：2005-01-26

    申请人： Jaime Bunda ,  Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    发明人： Jaime Bunda ,  Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    IPC分类号： C07D209/44 ,  A61K31/4035

    CPC分类号： C07D209/44

    摘要： The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

    摘要翻译： 本发明涉及可用作神经激肽-1（NK-1）受体拮抗剂，速激肽抑制剂，特别是物质P的某些加氢异吲哚啉化合物。本发明还涉及包含这些化合物作为活性成分的药物制剂和 使用化合物及其制剂治疗某些疾病，包括呕吐，尿失禁，抑郁和焦虑。

    Quinoline Tachykinin Receptor Antagonists
    4.
    发明申请
    Quinoline Tachykinin Receptor Antagonists 审中-公开
    喹啉速激肽受体拮抗剂

    公开(公告)号：US20070293492A1

    公开(公告)日：2007-12-20

    申请号：US11791241

    申请日：2005-11-29

    申请人： Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    发明人： Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    IPC分类号： A61K31/47 ,  A61K31/535 ,  A61P25/00 ,  C07D215/38 ,  C07D413/02

    CPC分类号： C07D215/20 ,  C07D215/38 ,  C07D215/48 ,  C07D215/60 ,  C07D453/06

    摘要： The present invention is directed to certain quinoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

    摘要翻译： 本发明涉及可用作神经激肽-1（NK-1）受体拮抗剂，速激肽抑制剂，特别是物质P的某些喹啉化合物。本发明还涉及包含这些化合物作为活性成分的药物制剂和 使用化合物及其制剂治疗某些疾病，包括呕吐，尿失禁，抑郁和焦虑。

    8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists
    5.
    发明申请
    8-Phenyl-5,6,7,8-Hydroquinoline Tachykinin Receptor Antagonists 审中-公开
    8-苯基-5,6,7,8-氢喹啉速激肽受体拮抗剂

    公开(公告)号：US20080039494A1

    公开(公告)日：2008-02-14

    申请号：US11667908

    申请日：2005-11-29

    申请人： Jianming Bao ,  Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    发明人： Jianming Bao ,  Robert DeVita ,  Jinlong Jiang ,  Sander Mills

    IPC分类号： A61K31/47 ,  A61P29/00 ,  C07D217/22

    CPC分类号： C07D215/20 ,  C07D215/22 ,  C07D215/60

    摘要： The present invention is directed to certain 8-phenyl-5,6,7,8-hydroquinolinecompounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

    摘要翻译： 本发明涉及可用作神经激肽-1（NK-1）受体拮抗剂的某些8-苯基-5,6,7,8-氢喹啉化合物，以及速激肽抑制剂，特别是物质P。本发明还涉及 其中包含这些化合物作为活性成分的药物制剂以及化合物及其制剂在治疗某些疾病（包括呕吐，尿失禁，抑郁和焦虑）中的用途。

    2,6-Disubstituted piperiddines as modulators
    8.
    发明申请
    2,6-Disubstituted piperiddines as modulators 失效
    2,6-二取代的哌啶作为调节剂

    公开(公告)号：US20070179158A1

    公开(公告)日：2007-08-02

    申请号：US10586765

    申请日：2005-01-14

    申请人： Lihu Yang ,  Sander Mills ,  Changyou Zhou ,  Stephen Goble ,  Alexander Pasternak

    发明人： Lihu Yang ,  Sander Mills ,  Changyou Zhou ,  Stephen Goble ,  Alexander Pasternak

    IPC分类号： A61K31/506 ,  A61K31/4745 ,  A61K31/46 ,  C07D471/02

    CPC分类号： C07D519/00 ,  C07D451/02 ,  C07D451/04 ,  C07D451/06

    摘要： The present invention is further directed to compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R16, R17, R18, R19, R20, R21 and R22 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

    摘要翻译： 本发明还涉及式（I）的化合物：其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9，R 9， R 10，R 16，R 17，R 18，R 19，R 16， R 20，R 21，R 22和R 22如本文所定义），其是趋化因子受体活性的调节剂，并且可用于 预防或治疗某些炎性和免疫调节性疾病和疾病，过敏性疾病，特应性病症，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及自身免疫病态如类风湿性关节炎和动脉粥样硬化。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及趋化因子受体的疾病中的用途。